Keyword Analysis & Research: eculizumab
Keyword Research: People who searched eculizumab also searched
Search Results related to eculizumab on Search Engine
-
Eculizumab - Wikipedia
https://en.wikipedia.org/wiki/Eculizumab
WebEculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis, and …
DA: 49 PA: 79 MOZ Rank: 73
-
SOLIRIS® (eculizumab) Home | HCP Site
https://solirisnmosd-hcp.com/
WebSOLIRIS ® (eculizumab) is the first FDA-approved complement inhibitor indicated for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). 1
DA: 55 PA: 51 MOZ Rank: 66
-
Eculizumab Uses, Side Effects & Warnings - Drugs.com
https://www.drugs.com/mtm/eculizumab.html
WebWhat is eculizumab? Eculizumab is used in adults to treat myasthenia gravis or neuromyelitis optica spectrum disorder. Eculizumab is also used to prevent the breakdown of red blood cells in adults with paroxysmal nocturnal hemoglobinuria.
DA: 51 PA: 14 MOZ Rank: 26
-
Soliris® (eculizumab) | Alexion
https://alexion.com/en/our-medicines/medicines/soliris
WebSOLIRIS is indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti ...
DA: 58 PA: 63 MOZ Rank: 44
-
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183484/
WebApr 7, 2020 · Abstract. The terminal complement protein (C5) inhibitor eculizumab (Soliris ®) is the first agent to be specifically approved in the EU, USA, Canada and Japan for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 water channel autoantibody (AQP4-IgG) seropositive and (in the EU only) for those with ...
DA: 62 PA: 78 MOZ Rank: 89
-
Soliris (eculizumab) dosing, indications, interactions, adverse …
https://reference.medscape.com/drug/soliris-eculizumab-342875
Webeculizumab (Rx) Brand and Other Names: Soliris. Classes: Monoclonal Antibodies; Complement Inhibitors. Print. Dosing & Uses. AdultPediatric. Dosage Forms & Strengths. injectable solution....
DA: 67 PA: 69 MOZ Rank: 9
-
Eculizumab: Uses, Interactions, Mechanism of Action | DrugBank …
https://go.drugbank.com/drugs/DB01257
WebMay 16, 2007 · Eculizumab is a monoclonal antibody that prevents the activation of terminal complement in some autoimmune conditions. 7,1,2 Eculizumab has a long duration of action. 7 Patients taking this medication should be vaccinated against Neisseria meningiditis as serious meningococcal infections have occurred in the past. 7,2
DA: 18 PA: 63 MOZ Rank: 62
-
FDA approves first treatment for neuromyelitis optica spectrum …
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central
WebJune 27, 2019. The U.S. Food and Drug Administration today approved Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult...
DA: 88 PA: 89 MOZ Rank: 98
-
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal
https://www.nejm.org/doi/full/10.1056/NEJMoa061648
WebSep 21, 2006 · Eculizumab (Soliris, Alexion Pharmaceuticals) is a humanized monoclonal antibody directed against the terminal complement protein C5. 13 In a preliminary, 12-week, open-label clinical study...
DA: 13 PA: 2 MOZ Rank: 63
-
Eculizumab | Memorial Sloan Kettering Cancer Center
https://www.mskcc.org/cancer-care/patient-education/medications/adult/eculizumab
WebDec 12, 2022 · What is this drug used for? It is used to treat a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). It is used to treat a blood and kidney disease called atypical hemolytic uremic syndrome (aHUS). It is used to treat myasthenia gravis. It is used to treat a health problem called neuromyelitis optica spectrum disorder (NMOSD).
DA: 36 PA: 8 MOZ Rank: 9